Andrea Biondi
IRCCS San Gerardo dei Tintori · University of Milano Bicocca · EsPhALL Network/ BFM Study Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrea Biondi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:49 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05869279 · Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic LeukemiaFondazione Matilde Tettamanti Menotti De Marchi Onlus · recruiting · B-cell NHL, CLL · principal investigator
- N/ANCT04090268 · Precision Exercise in Children With Malignant HemopathiesUniversity of Milano Bicocca · unknown · Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T Cell · principal investigator
- Ph3NCT03007147 · Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaChildren's Oncology Group · active not recruiting · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia · principal investigator
- Ph2NCT00287105 · Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in ChildrenRennes University Hospital · completed · Acute Lymphoblastic Leukemia, Philadelphia Chromosome · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT03007147
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:49 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- 625 citationsRCR 15.2
- 349 citationsRCR 8.5
- 298 citationsRCR 6.4
- 246 citationsRCR 6.1
- 224 citationsRCR 7.9
- Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.J Clin Oncol · 2009215 citationsRCR 5.2
- Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.J Clin Invest · 2020167 citationsRCR 6.4
- 128 citationsRCR 3.2
- 115 citationsRCR 2.5
- Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.Leukemia · 2005102 citationsRCR 2.3